---
schema_version: "secwatch.filing_event.v1"
accession: "0001773427-24-000016"
form_type: "8-K"
ticker: null
cik: "0001773427"
company_name: "SpringWorks Therapeutics, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:45:43.915431+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SpringWorks Q1 OGSIVEO revenue $21M; net loss widens to $87.4M

## Summary
- OGSIVEO net product revenue $21.0M in first full quarter of U.S. launch.
- Net loss $87.4M ($1.18 per share) vs. $73.4M ($1.18 per share) in Q1 2023, driven by higher SG&A and R&D costs.
- Cash, equivalents and marketable securities $573.0M as of March 31, 2024.
- EMA validated MAA for nirogacestat in desmoid tumors; rolling NDA submission for mirdametinib in NF1-PN initiated.
- Phase 2b ReNeu trial results accepted for oral presentation at 2024 ASCO Annual Meeting.

## SEC filing metadata
- accession: 0001773427-24-000016
- form_type: 8-K
- cik: 0001773427
- company_name: SpringWorks Therapeutics, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/0001773427-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/swtx-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001773427-24-000016
- JSON: https://secwatch.observer/filing/0001773427-24-000016.json
- Plain text: https://secwatch.observer/filing/0001773427-24-000016.txt

## Key facts
- Earnings Releases
  SpringWorks Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.0 million, net income $87.4 million, EPS $1.18 per share.
  - Period: the quarter ended March 31, 2024
  - Revenue: $21.0 million
  - Net income: $87.4 million
  - EPS: $1.18 per share
  - Result: reported results
  source text: reference in such filing. --- EX-99.1 (EX-99.1) --- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates – Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/0001773427-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.